Antigenics says melanoma drug shows promise

10/11/2005 | Wall Street Journal, The

The company said preliminary results from a late-stage trial suggest its Oncophage vaccine extended the survival of advanced cancer patients by about eight months over standard therapies. The personalized cancer treatment uses malignant tumor tissue to prompt a patient's immune system to attack the cancer. Once data from the Phase III trial are analyzed, Antigenics plans to conduct a final trial before applying for FDA approval.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Medical Device Reimbursement Specialist - Regional
Alcon
Fort Worth , TX
Assistant General Counsel/Senior Corporate Counsel - Healthcare Law Group
Genentech
94080, CA
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX